Analysts Set Omnicell, Inc. (NASDAQ:OMCL) PT at $46.71

Key Points

• Omnicell, Inc. has received a consensus rating of "Moderate Buy" from seven analysts, with three holding ratings and four assigning buy ratings.
• The average target price for Omnicell shares is $46.71, with recent adjustments by firms like Wells Fargo and Bank of America increasing their target prices.
• Omnicell reported better-than-expected earnings with a Q2 EPS of $0.45, surpassing the consensus estimate of $0.30, and revenue of $290.56 million, reflecting a 5.0% year-over-year increase.

Shares of Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $46.7143.

A number of equities research analysts recently weighed in on OMCL shares. Piper Sandler lowered their target price on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a report on Monday, August 11th. Wells Fargo & Company boosted their price objective on Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a report on Monday, July 21st. Bank of America raised their target price on Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a report on Friday, May 23rd. Finally, Wall Street Zen cut Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th.

Omnicell Stock Down 2.8%

Shares of NASDAQ:OMCL traded down $0.91 during trading on Friday, reaching $31.86. 512,120 shares of the stock were exchanged, compared to its average volume of 509,246. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24. Omnicell has a 1-year low of $22.66 and a 1-year high of $55.74. The stock has a fifty day moving average of $30.59 and a two-hundred day moving average of $31.21. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of 63.72, a price-to-earnings-growth ratio of 7.16 and a beta of 0.82.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The business had revenue of $290.56 million during the quarter, compared to the consensus estimate of $275.57 million. During the same quarter last year, the firm posted $0.51 EPS. Omnicell's revenue was up 5.0% compared to the same quarter last year. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Research analysts anticipate that Omnicell will post 1.09 earnings per share for the current fiscal year.

Institutional Trading of Omnicell

Several institutional investors and hedge funds have recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new position in Omnicell during the second quarter worth about $26,000. GAMMA Investing LLC lifted its position in shares of Omnicell by 37.1% during the 2nd quarter. GAMMA Investing LLC now owns 1,694 shares of the company's stock worth $50,000 after buying an additional 458 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in shares of Omnicell in the 4th quarter worth approximately $101,000. Corton Capital Inc. purchased a new position in shares of Omnicell in the 4th quarter worth approximately $208,000. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Omnicell by 385.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company's stock valued at $146,000 after acquiring an additional 3,932 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.